Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals

Pediatric Infectious Disease Journal

Volumn 24, Issue 10, 2005, Pages 867-873

  Ramos, José T ^a   De José, María Isabel ^b   Dueñas, Joaquín ^c   Fortuny, Claudia ^d   González Montero, Raúl ^e   Mellado, María José ^b   Mur, Antonio ^f   Navarro, Marisa ^g   Otero, Carmen ^h   Pocheville, Itziar ⁱ   Muñoz Fernández, María Angeles ^g   Cabrero, Esther ^j  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d HOSPITAL SANT JOAN DE DÉU   (Spain)

^e Hospital Sant Joan   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ HOSPITAL DE CRUCES   (Spain)

^j ABBOTT LABORATORIES   (Spain)

more..

Author keywords

Antiretroviral experienced; Children; Human immunodeficiency virus; Lopinavir ritonavir

Indexed keywords

ABACAVIR; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMPRENAVIR; AMYLASE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHOLESTEROL; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; DIDANOSINE; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; UNINDEXED DRUG; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; NONHUMAN; OPEN STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS GENE; VIRUS LOAD; VOMITING;

EID: 26944478140     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000180574.18804.90     Document Type: Article

References (31)

1. Gortmaker S, Hughes M, Oyomopito R, et al. Impact of introduction of protease inhibitor therapy on reductions in mortality among children and youth infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
2. De Martino MM, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA. 2000;284:190-197.
3. Sánchez-Granados J, Ramos JT, Rojo P, et al. Impact of HAART on the survival and disease progression in HIV-1-infected children. Pediatr Infect Dis J. 2003;22:863-867.
4. Watson DC, Farley JJ. Efficacy and adherence to highly active antiretroviral therapy (HAART) in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1999;18:682-689.
5. Van Dike RB, Lee S, Jonhson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109:e61.
6. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J. 2003;22:77-84.
7. Kovacs A, Burchett S, Khuory M, et al. Virologic and immunologic responses in children with advanced HIV disease on a new HAART regimen (PACTG 366). Paper presented at: Eighth Conference on Retroviruses and Opportunistic Infections, 2001, Chicago. Abstract 684.
8. Krogstad P, Lee S, Jonhson G, et al. Nucleoside analog reverse transcriptase inhibitors plus nevirapine, nelfinavir or ritonavir in stable antiretroviral therapy-experienced HIV-infected children. Clin Infect Dis. 2002;34:991-1001.
9. Hoffman F, Notheis G, Wintergest U, et al. Comparison of ritonavir plus saquinavir and nelfinavir plus saquinavir containing regimens as salvage therapy in children with human immunodeficiency type 1 infection. Pediatr Infect Dis J. 2000;19:47-51.
10. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus infected children. Pediatr Infect Dis J. 2003;22:216-223.
11. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113-128.
12. Centers for Diseases Control. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR. 1994;43(RR-12):1-10.
13. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346: 2039-2046.
14. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease-inhibitor-experienced patients. J Infect Dis. 2002;185:599-607.
15. Hall CS, Raines Ch P, Barnett SH, Moore RD, Gallant JE. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. AIDS. 1999;13:1207-12.
16. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: ACTG 359. J Infect Dis. 2000;182:1375-1384.
17. trough inhibitory quotient predicts virologic response to ABT-378/ritonavir (ABT-378/r) therapy in treatment-experienced patients [abstract], AIDS. 2000;14(suppl 4): S12.AbstractPL 9.41.
18. Romano L, Peduzzi C, Venturi G, et al. Treatment with lopinavir/ritonavir in heavily preetreated subjects failing multiple antiretroviral regimens in clinical practice. J Acquir Immune Defic Syndr. 2002;30:533-534.
19. Gilleece YC, Nad Q, Morlese JF, et al. The efficacy of lopinavir in individuals experiencing protease inhibitor failure. J Acquir Immune Defic Syndr. 2003;32:238-240.
20. Gutierrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir- containing regimens. J Acquir Immune Defic Syndr. 2003;33:594-600.
21. Guiard-Schmid JB, Poirier JM, Meynard JL, et al. High variability plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother. 2003;47:986-990.
22. Mallon PW, Ray J, Cooper DA. Effect of therapeutic drug monitoring in outcome in antiretroviral experienced HIV-individuals. J Clin Virol. 2003;223-227.
23. Sleasman JW, Nelson RP, Goodenow MM, et al. Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocytes lineages. J Pediatr. 1999;134: 597-606.
24. Martinez-Picado J, Saavara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol. 1999;73:3744-3752.
25. Mo H, Lu L, King M, et al. Impaired fitness of HIV-1 mutants that confer resistance to lopinavir in vivo. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA. Washington, DC: American Society for Microbiology; Abstract H-2061.
26. Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virologic response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1 infected patients receiving lopinavir/ritonavir therapy. Antiviral Ther. 2002;7:165-174.
27. Bongiovanni M, Bini T, Adorni F, et al. Virological success of lopinavir/ ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. Antivir Ther. 2003;8:209-214.
28. Monno L, Saracino A, Scudeller L, et al. HIV-1 phenotypic susceptibility to lopinavir and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. J Acquir Immune Defic Syndr. 2003;33:439-447.
29. Ramos JT, Carreno P, Fortuny C, et al. Salvage therapy with lopinavir-ritonavir (Kaletra) in heavily pretreated children. In: Ninth Retroconference on Retroviruses and Opportunistic Infections, February 2002, Seattle, WA. Abstract 810-W.
30. Ramos JT, Carreno P, Fortuny C, et al. Response to lopinavir-ritonavir (Kaletra) in heavily pretreated children. In: Fourteenth World AIDS Conference, July 7, 2002, Barcelona, Spain. Abstract TuPpB2052.
31. Ramos JT, Gonzalez Tome MI, Fortuny C, et al. Response to lopinavir-ritonavir (Kaletra) in children experienced with the 3 classes of antiretrovirals. In: Second International AIDS Congress, July 2003, Paris, France. Abstract 1096.